Literature DB >> 17236767

Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.

Tabish Equbal1, Om Silakari, Gundla Rambabu, Muttineni Ravikumar.   

Abstract

Protein farnesyltransferase (FTase) is a zinc-dependent enzyme that catalyzes the attachment of a farnesyl lipid group to the sulfur atom of a cysteine residue of numerous proteins involved in cell signaling including the oncogenic H-Ras protein. Pharmacophore models were developed by using Catalyst HypoGen program with a training set of 22 farnesyltransferase inhibitors (FTIs), which were carefully selected with great diversity in both molecular structure and bioactivity for discovering new potent FTIs. The best pharmacophore hypothesis (Hypo 1), consisting of four features, namely, one hydrogen-bond acceptor (HBA), one hydrophobic point (HY), and two ring aromatics (RA), has a correlation coefficient of 0.961, a root mean square deviation (RMSD) of 0.885, and a cost difference of 62.436, suggesting that a highly predictive pharmacophore model was successfully obtained. For the test series, a classification scheme was used to distinguish highly active from moderately active and inactive compounds on the basis of activity ranges. Hypo 1 was validated with 181 test set compounds, which has a correlation coefficient of 0.713 between estimated activity and experimentally measured activity. The model was further validated by screening a database spiked with 25 known inhibitors. The model picked up all 25 known inhibitors giving an enrichment factor of 10.892. The results demonstrate that the hypothesis derived in this study can be considered to be a useful and reliable tool in identifying structurally diverse compounds with desired biological activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17236767     DOI: 10.1016/j.bmcl.2006.12.087

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors.

Authors:  Hsin-Yuan Wei; Guan-Ju Chen; Chih-Lun Chen; Thy-Hou Lin
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

2.  Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines.

Authors:  Saeed Ghasemi; Soodabeh Davaran; Simin Sharifi; Davoud Asgari; Ali Abdollahi; Javid Shahbazi Mojarrad
Journal:  Adv Pharm Bull       Date:  2013-02-07

3.  Virtual lead identification of farnesyltransferase inhibitors based on ligand and structure-based pharmacophore techniques.

Authors:  Qosay A Al-Balas; Haneen A Amawi; Mohammad A Hassan; Amjad M Qandil; Ammar M Almaaytah; Nizar M Mhaidat
Journal:  Pharmaceuticals (Basel)       Date:  2013-05-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.